$LLY Recent News Drug-maker earnings come in ahe
Post# of 5325
Drug-maker earnings come in ahead of views, but stocks aren't rewarded 10:45 a.m. Oct. 23, 2013 - Russ Britt
Stock futures retreat; Cat misses on earnings 7:42 a.m. Oct. 23, 2013 - William L. Watts
Eli Lilly net profit down 9.3%, revenue rises 6:03 a.m. Oct. 23, 2013 - MarketWatch.com
Eli Lilly 3Q adj. EPS FactSet estimate was $1.04 5:39 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q revenue up 6% to $5.77 billion 5:38 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q net income down 9% to $1.20 billion 5:37 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q adj. EPS up 41% to $1.11 5:35 a.m. Oct. 23, 2013 - Sara Sjolin
Boeing, AT&T, Caterpillar are stocks to watch 4:31 a.m. Oct. 23, 2013 - Sue Chang
The market in a minute: Playing with volatility 7:42 a.m. Oct. 21, 2013 - The Trading Deck
Eli Lilly downgraded to underperform by Jefferies 8:21 a.m. Oct. 11, 2013 - Ben Eisen
Tesla stuck in reverse, Herbalife loses momentum 3:35 p.m. Oct. 3, 2013 - Sue Chang
Lilly unveils $5 billion share-buyback program 7:02 a.m. Oct. 3, 2013 - MarketWatch.com
J.C. Penney snaps losing streak; Facebook tops $50 3:36 p.m. Sept. 26, 2013 - Sue Chang
3 dividend stocks for worried investors 5:00 a.m. Sept. 9, 2013 - Jeff Reeves
Renaissance Technologies' top dividend picks 3:25 p.m. Aug. 23, 2013 - Insider Monkey
Tuesday’s movers: Airline stocks, Apple 3:32 p.m. Aug. 13, 2013 - Maria LaMagna
U.S. stocks rise with help from Apple Inc. 3:21 p.m. Aug. 13, 2013 - Kate Gibson
Updates, advisories and surprises 5:01 p.m. July 24, 2013 - MarketWatch
Lilly shares up on higher earnings, lower expenses; Elan also rises 11:00 a.m. July 24, 2013 - Russ Britt
Apple, AT&T, Boeing are stocks to watch Wednesday 8:24 a.m. July 24, 2013 - Maria LaMagna
4 Healthcare Sector Dogs Hype 13% To 17% October Upsides; 4% To 7.5% Downsides 7:02 p.m. Nov. 8, 2013 - Seeking Alpha
Multiple Reasons To Buy Incyte 3:25 p.m. Nov. 8, 2013 - Seeking Alpha
Lower-than-Expected Loss at OncoGenex - Analyst Blog 3:20 p.m. Nov. 8, 2013 - Zacks.com
Eli Lilly Goes Down The Hill As Patents Expire 1:46 p.m. Nov. 8, 2013 - Seeking Alpha
3 Huge Healthcare Trends Can Fatten Your Portfolio 4:00 a.m. Nov. 8, 2013 - InvestorPlace.com
Stocks to Sell or Short: The Seven Least Preferred Stocks at UBS 8:28 a.m. Nov. 7, 2013 - 247WallSt.com
China Drags on Western Profits 12:23 a.m. Nov. 6, 2013 - WSJ.com
Prolific Selling - Hussman's High-Impact Moves Mirror Insiders 9:51 a.m. Nov. 5, 2013 - GuruFocus.com
We Like What We're Seeing In Big Pharma 4:15 a.m. Nov. 5, 2013 - Seeking Alpha
Drug Makers Get a Shot in the Arm 7:26 p.m. Nov. 3, 2013 - WSJ.com
Merck - Surprised Weakness In JANUVIA Is Causing Renewed Worries For Investors 2:10 p.m. Oct. 29, 2013 - Seeking Alpha
Eli Lilly Bulls: How Will 2014 Treat You? 10:08 a.m. Oct. 29, 2013 - Seeking Alpha
'Fast Money' Recap: Apple to the Core 5:00 a.m. Oct. 29, 2013 - TheStreet.com
Merck Profit Falls on Lower Sales 1:32 p.m. Oct. 28, 2013 - WSJ.com
Eli Lilly: Cymbalta Patent Expiry Quantified 12:48 p.m. Oct. 28, 2013 - Seeking Alpha
Narrower-than-Expected Q3 Loss at ImmunoGen - Analyst Blog 10:30 a.m. Oct. 28, 2013 - Zacks.com
4 Biotech Stocks Making Headlines 10:25 a.m. Oct. 28, 2013 - Wall St. Cheat Sheet
Our Retirement Income Portfolio And Its 3rd Quarter Review 4:22 p.m. Oct. 25, 2013 - Seeking Alpha
Apple’s Mavericks Breaks Records, JPMorgan’s Legal Concerns, and 3 More Hot Stocks 1:37 p.m. Oct. 25, 2013 - Wall St. Cheat Sheet
Amarantus' LymPro May Be More Crucial For Alzheimer's Treatment Than We Think 8:38 a.m. Oct. 25, 2013 - Seeking Alpha
Morning Research: Eli Lilly & Co., Bristol-Myers Squibb Co., Allergan Inc., and Endo Health Solutions Inc. 11:27 a.m. Nov. 4, 2013 - PR Newswire
Fitch: Pharmaceutical Cost Cutting Still Includes R&D for Some 11:18 a.m. Nov. 4, 2013 - BusinessWire
Through 2022, Growth in the Neuropathic Pain Drug Market Will be Constrained by the Genericization of Sales-Leading Agents from Eli Lilly/Shionogi, Endo/Grunenthal and Pfizer 9:00 a.m. Nov. 4, 2013 - PR Newswire
Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes 9:00 a.m. Nov. 1, 2013 - PR Newswire
Dividend, Quarterly Report, Recognition, Study Results, and New Drug Application - Research Report on Pfizer, Lilly, Regeneron, Vertex, and GSK 9:00 a.m. Nov. 1, 2013 - PR Newswire
In Russia, the Use of Premium-Priced Novel Agents Will Expand the Acute Coronary Syndrome Market Through 2017 10:00 a.m. Oct. 29, 2013 - PR Newswire
Lessons From Hurricane Sandy: American College of Endocrinology (ACE) Urges Those With Diabetes to Plan Ahead 9:50 a.m. Oct. 29, 2013 - BusinessWire
The Alzheimer's Disease Drug Market Will Triple by 2022, Driven Largely by the Projected Launch of Eli Lilly's Solanezumab 9:00 a.m. Oct. 29, 2013 - PR Newswire
FDA Approves Addition to CIALIS® (tadalafil) Product Label 8:00 a.m. Oct. 25, 2013 - PR Newswire
Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets 5:00 p.m. Oct. 24, 2013 - PR Newswire
Critical Alerts For LinkedIn, MasterCard, News Corp, Eli Lilly, and ASML Holdings Released By InvestorsObserver 9:31 a.m. Oct. 24, 2013 - PR Newswire
Returning Value to Shareholders through Dividends, Strong Financial Results, and Regulatory Approvals - Research Report on Lilly, Illumina, Regeneron, Teva, and Vanda Pharmaceuticals 8:00 a.m. Oct. 24, 2013 - PR Newswire
FDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer 6:31 a.m. Oct. 23, 2013 - PR Newswire
Lilly Reports Third-Quarter 2013 Results 6:30 a.m. Oct. 23, 2013 - PR Newswire
Jackson Tai Elected to Lilly Board of Directors 10:21 a.m. Oct. 22, 2013 - PR Newswire
Jackson Tai Elected to Lilly Board of Directors 8:00 a.m. Oct. 22, 2013 - PR Newswire
Lilly Declares Fourth-Quarter 2013 Dividend 4:15 p.m. Oct. 21, 2013 - PR Newswire
ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Versatility of Novel Gene Expression and Control Technology 12:30 p.m. Oct. 21, 2013 - GlobeNewswire
The Carlyle Group and AlpInvest Assume Management of Two Indiana Life Sciences Funds of Funds Totaling $130 Million 7:00 a.m. Oct. 17, 2013 - BusinessWire
Awareness Programs, Restructuring Efforts, Conference Calls, Marketing Authorization Withdrawal and Clinical Trial Commencement - Research Report on Lilly, Teva, Elan, Zoetis, and Boston Scientific 8:00 a.m. Oct. 16, 2013 - PR Newswire